Drugmakers and the Obesity Market
When it comes to the drug industry, three heavyweights basically corner the market for obesity treatments: Xenical from Roche (RHHBY), Belviq from Arena Pharmaceuticals (ARNA) and Qsymia, a product of Vivus (VVUS).
Not expected to gain FDA approval until 2014 or 2015, Contrave from Orexigen (OREX) may eventually give the others a run for their money but not in the short-term.
Unfortunately, no matter how we choose to prevent and treat obesity, the real battle has just begun. Good, bad or otherwise, so has the uptrend in related stocks.